BARDA Biodefense Medical Countermeasure Development — CFDA 93.360

BARDA countermeasure obligations at $2.34 billion

USAspending.gov records $2,343,557,106.30 in obligations under CFDA 93.360. One hundred thirty awards produce that stock. A simple average is about $18.0 million per award — far larger than a typical NIH investigator grant and consistent with advanced-development awards. That average is a quotient of two packet totals, not a typical manufacturing-lot cost or a per-dose price.

The assistance-listing title is BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), BIODEFENSE MEDICAL COUNTERMEASURE DEVELOPMENT. CFDA 93.360 is the identifier. Other HHS preparedness listings tagged under different CFDA numbers are not mixed into the $2.34 billion. Combining those codes would invent a combined countermeasure total this packet does not contain.

98 recipients across 34 states

Ninety-eight recipients share 130 awards, or about 1.3 award records per recipient on average. Splitting $2.34 billion evenly would assign about $23.9 million per recipient. That near one-to-one pattern is a short roster of developers and partners, not a dense university portfolio. The packet does not list the 98. Recipient count is the organizational headcount, not a census of products, doses, or clinical-trial sites.

Thirty-four states in the geographic count leave a large share of the map uncoded. Advanced-development dollars concentrate where the 98 named organizations sit. Place-of-performance amounts are on the program table.

Award count is not a product or dose count

Among preparedness-research listings, 93.360 is a low-row, high-dollar file: 130 awards against 98 recipients. Multi-year awards and amendments can inflate award count relative to unique products. Award count is therefore a weak proxy for “number of medical countermeasures.” Recipients (98) tell you how many named organizations sit on the extract; awards (130) tell you how many assistance rows were stored.

The packet does not report EUA statuses, stockpile doses, or trial enrollments. Citing 130 as vaccines or treatments would be a unit error. Keep the units straight: dollars, awards, recipients, states.

Obligations versus BARDA outlays

The $2.34 billion is an obligation total from USAspending.gov. Outlays — cash paid against BARDA awards — are not in the packet. A developer can show a large obligation stock while manufacturing follows a later calendar. Deobligations and upward adjustments both move the total. A remaining-balance question is an outlay question this extract does not answer.

Use CFDA 93.360 to size this BARDA countermeasure listing in the assistance file. Do not use it as a stockpile dashboard. Those series live elsewhere. This page reports the obligation book tagged 93.360.

What the 93.360 tables omit

The BARDA hub lists award-backed obligations from USAspending.gov. It is not a product registry, not a Strategic National Stockpile inventory, and not a clinical-trial index. Series that never appear as assistance awards will not show up in the $2,343,557,106.30. That omission is definitional rather than a gap in the 130 award rows.

Place-of-performance on 34 states is a coding field. Read the program page before treating those cells as equal shares. Recipient dollars, if shown on the hub, are still obligation amounts, not cash already spent on manufacturing.

Where the 93.360 table lives

The program page overlays these four facts. The all-programs index ranks 93.360 among other assistance listings. Agency pages show awarding-agency rollups that may include this CFDA among other HHS listings. For 93.360 only, start on the program page.

CFDA 93.360’s 130 awards spread $2,343,557,106.30 across 98 recipients and 34 states. Quote award count as a record count, recipient count as the organizational headcount, and dollars as obligations from USAspending.gov. About 1.3 award records per recipient is the density story on this listing. Outlays remain a separate column. Source: USAspending.gov assistance awards. Read 93.360 as a BARDA advanced-development book: 98 organizations, 130 awards, 34 states, and $18.0 million averages that describe countermeasure awards rather than investigator grants. The $2.34 billion remains an obligation stock on USAspending.gov.

Questions

How much is obligated for BARDA biodefense medical countermeasure development?

USAspending.gov records $2,343,557,106.30 in obligations for CFDA 93.360. SpendingVault indexes 130 awards, 98 recipients, and 34 states. The figure is an obligation sum from assistance awards, not an outlay and not a dose count. CFDA 93.360’s $2.34 billion is the USAspending obligation stock.

How many awards does CFDA 93.360 carry?

The listing shows 130 awards against 98 recipients, or about 1.3 award records per recipient. A simple average is about $18.0 million per award. Award count is not a product or dose count. Recipient dollars are on the program page.

How many organizations receive 93.360 awards?

The extract lists 98 recipients. Those are organizational recipients on assistance awards tagged 93.360. Geographic coding covers 34 states. The packet does not name the 98 or publish product or stockpile data. Recipient count is the organizational headcount.

Is $2.34 billion already spent on medical countermeasures?

Not necessarily. Obligations are commitments. Outlays are payments. CFDA 93.360’s indexed total is the obligation stock from USAspending.gov. This page does not report cash drawn, remaining balances, or doses delivered. The $2.34 billion on 130 awards is the obligation figure.